|Publication number||US3424842 A|
|Publication date||28 Jan 1969|
|Filing date||4 May 1965|
|Priority date||9 May 1964|
|Also published as||DE1228029B, DE1228029C2|
|Publication number||US 3424842 A, US 3424842A, US-A-3424842, US3424842 A, US3424842A|
|Original Assignee||Merck Ag E|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (11), Referenced by (74), Classifications (15)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent US. Cl. 42494 Int. Cl. A61k 9/00; A61j 3/10 24 Claims ABSTRACT OF THE DISCLOSURE Nongranulated, directly dry compressed pharmaceutical tablets of therapeutically active compounds incapable of being dry compressed to acceptable tablets directly without any preparation, the preparation in this case being homogeneously introducing 1-10% by weight of certain powdery, dry adhesives such as cellulose, gelatin, alginic acid and salts thereof, and others.
This invention relates to a process for the manufacture of pills, tablets, and the like, and in particular to a process in which pills are produced directly from powders without the aid of an intermediate granulating step.
Normally, the tabletting of powdery pharmaceuticals or mixtures is only possible if the starting material is previously converted, by using a dry or wet process, into fiowable granules having a particle size of about 0.05 to 2 mm. and an average particle size of about 0.2 to 0.5 mm. Only few pharmaceuticals possess a sufiicient cohesiveness and flowability that they can be compressed to tablets directly without any preparation.
Many attempts have been made to avoid this inconvenient additional granulation step. Thus, it was proposed to moisten the powdery material with aqueous or nonaqueous solvents, said solvents being removed by drying after the tablets are compressed. Moreover, many roughly pulverized substances can be made into tablets without further preparation by adding starch containing 10% cocoa butter. However, upon analysis of these processes, it is seen that the granulation step is merely substituted by another step (moistening or drying, respectively), so that these processes do not solve the problem in an efiicient manner.
It was also proposed to make powdery mixtures tablettable by adding certain materials. For this purpose, there were suggested, for instance, whey powder, calciumsilicate aerogel, or microfine-grained silica gel. The amounts to be added of the first-mentioned two compounds are disproportionately large (30 or 20%, respectively, all percentages given now and hereinafter being weight percentages).
The principal object of this invention, therefore, is to provide an improved process for the production of pills, tablets, and the like, said process being characterized by the absence of a granulating step.
Another object is to provide an improved pill which is storable yet rapidly disintegratable in solution.
Upon further study of the specification and claims, other objects and advantages of the present invention will become apparent.
For the purposes of this invention, pills, tablets, and the like are defined merely as tablets, it being understood that this term embraces all shapes having a predetermined geometry, e.g., the configuration of the die. In general, the particle size of the tablets is in the range of 3 to 30, more commonly 5 to 25 mm.
To attain the objects of this invention, a process is provided which is based on the discovery that powdery mixtures can be easily and efliciently compressed into See tablets without a preceding granulation step, if physiologically compatible powdery polyethylene glycols, gelatin, and/or polysaccharides-with the exception of starchare added to the powdery pharmaceutical composition.
In this application, the expression polysaccharides shall also include functionally varied as, for instance, substituted, partially oxidized, or partially reduced derivatives of polysaccharides.
Furthermore, it was discovered that adding these compounds in amounts between 1 and 10%, preferably 2 and 5%, based on the weight of the total powdery composiiton, is suflicient, thereby avoiding the disadvantage of adding large amounts of the above-mentioned compounds to the tablets. It was indeed surprising that these added compoundshereinafter called dry adhesiveswould work in view of the fact that they do not seem to possess any adhesive or gluing eifect in the dry state.
The polyethylene glycols that are used are normally solid polymers having, in general, a molecular weight in the range of about 600 to 7000, preferably 3500 to 4500. The gelatin that is used is the usual colloidal protein used for numerous purposes in the pharmaceutical industry. Lastly, suitable polysaccharides are all those found in this large class with the exception of starch, the literature being the source for a large catalogue of these compounds. It is apparent, then, that the submission of the following numerous specific examples is not an attempt to describe the whole class, but is merely for purposes of illustration, for instance, dextrin, inulin, cellulose, cellulose derivatives such as carboxymethyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, alginic acids and their salts, hemicelluloses, such as galactomannan, agar-agar, tragacanth, gum arabic, pectins, such as dried apple pectin or sodium amylopectinglycolate.
The molecular weight of these substances can vary considerably. It can be as low as about 1000, Le, in some dextrins, and as high as about 1,000,000, f.e., in some celluloses. Preferably, however, polysaccharides having molecular weights between about 10,000 and about 300,000 are suitable for the purpose of the invention.
According to the invention, it is, of course, possible to apply plant preparations consisting essentially of polysaccharides which are prepared from plant material being rich in such polysaccharides. Such preparation can, for instance, be obtained from carob, sea-weed, mosses, guar seeds. They may contain small amounts of other substances as long as these are physiologically compatible.
Among all these dry adhesives, the use of a native beech cellulose powder exhibiting the following characteristics has been particularly advantageous:
BEECH CELLULOSE TABLE Average polymerisation degree (determined according to Jayme-Wellm) 620-680 Specific surface (determined according to Blaine), cm. -g. 6000 a-Cellulose content, percent 89-90 Lignin content, percent 0.05-0.08
pH in 5% aqueous suspension 4.95 .3 Ash content, percent 0.1-0.2 Resin content (extracted with methanol/benzene 1:1), percent 0.2-0.4 Piled Weight, g.-l.- 350 Calorific value, kcal. -kg. 3800 Average particle size 1040,u
Among these dry adhesives are also found such compounds which have already been used for the preparation of granules by the wet method. However, for this purpose, these compounds always had to be dissolvedcompletely or partiallyin a solvent. According to the process of the invention, however, the dry adhesives are added in the form of a powder to the powdery mixture of the active compounds, fillers, disintegrating agents, and polishing compounds; and in this way-after the homogeneous mixing or grinding of all components-a compressible product is obtained. For poorly flowing powdery mixtures it is appropriate to use, during the course of tabletting, suitable stirring, shaking, or vibrating devices, preferably special filling devices, such as the Riihrkarnmer-Fiillschuh (stirring chamber filling shoe).
For the purposes of this invention, the term powder is defined as particulate matter having a particle size less than about 2 mm., particularly less than about 1 mm. The preferred particle size range of the dry adhesive is about 10 to about 2 mm.
According to the physical properties of the active compounds and/or according to the method of using the tablets (for instance, readily disintegratable tablets such as aspirin, or slowly dissolving tablets such as suckers, etc.), any of the mentioned dry adhesives can be used. It is most advisable to determine by experiment the optimum dry adhesive for every single case. In this way it is possible to obtain tablets whose galenic properties are not inferior to those which are obtained by compression of a granulate. With respect to disintegration, the tablets obtained according to the process of this invention are even superior to the conventional tablets.
The process according to the invention extends to all usual shapes and products manufactured in galenic practice (the art of pharmacy or pill-making), especially to tablets, drage cores, and rodlets.
All usual tablet machines, preferably rotary tablet machines with force flow-feeding can be used for the process according to the invention. The tablets used in the examples below are made by using a rotary tablet machine with force flow-feeding type PIIS and P-IlI as manufactured by the firm of WilhelmFette, Schwarzenbek, near Hamburg, Germany.
In general, pressures between 1000 and 10,000 atmospheres are applied to compress the powder into tablets.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the specification and claims in any way whatsoever.
Example 1 Without a preceding granulation step, tablets of the following composition are compressed under aconventional pressure of about 3000 atmospheres; and the abrasion is determined in a 10 minute test in one or both of the following testing machines of the Engelmann tablet examination system:
(A) Abrasion drum (modified in solid clear polymethyl methacrylate) The basic composition of one tablet of 450 mg. is:
Mg. 2-methyl-3-o-tolyl-4(3H)quinazolinone 200 Lactose 180 Cornstarch 45 Talc 20 Finely divided silica 2.5 Magnesium stearate 2.5
In tablets possessing the respectively indicated content of dry adhesives, the amount of lactose is reduced correspondingly, so that all tablets possess the same final weight. As a dry adhesive there is used, in each case, a commercial type as indicated in the following table.
Abrasion, percent Content, Type of dry adhesive percent (F) (A) None 14 4 5 Alginic acid preparation (sodium 6 0.5
salts). 5 Polyethylene glycol (molecular 8.5 1. 5
weight, 4,000). 2 Cellulose powder l-4. 5 (H). 5 2.5-... Cellulose powder 1 5 0 5 2.5 Polyethylene glycol 5. Ethyl cellulose 8 1 5 Cat boxymethyl cellulose 7 l 5. Hydroxyethyl cellulose 10. 5 1. 5 5. Hydroxypropyl cellulos 9 0. 5 5. Tragacanth 9. 5 2 5... Gum arabic.. 8 1.5 5 Gelatin 10 1.8
Thus, it is seen that, by using the dry adhesives of the invention, tablet abrasion is reduced by 25 to 87%. Consequently, the tablets manufactured without a granulating step but according to this invention, are sufiiciently abrasion resistant and solid for pharmaceutical end uses. Furthermore, it is to be noted that mixtures of dry adhesives are embodied in this invention. Thus, the dry adhesive is selected from the group consisting of one or more polyethylene glycols, gelatin, one or more polysaccharides, with the exception of starch, and mixtures thereof.
Example 2 Analogously to Example 1 there are compressed tablets of the following composition and their abrasion is determined. The tablets manufactured according to this invention contain in each case 15 mg. of the dry adhesive specified in the table.
Mg. Dimethylaminophenyl dimethyl pyrazolone Phenacetin 100 Caffeine 20 Salicylic acid amide 50 Corn starch 30 Content, Type of dry adhesive Abrasion (F) percent 18 5 Polyethylene glyco1.-.. g 5 5- 0 5 7 5. 7 5. 11 5. 12 5. Galactomannans 7 5 Alginic acid preparation (sodium 2 salts). 5 Agar-agar. l0 5. Tragacanth. 1g 8 In summarizing the preceding table, it is seen that by using the dry adhesives of this invention, the abrasion of the manufactured tablets is reduced by 33 to 89%.
Example 3 Analogously to Example 1, tablets of the following compositon are compressed and their abrasion is determined. In each case, a part of the lactose is substituted by the indicated amount of the mentioned dry adhesive.
In this example, the reduction of abrasion by adding the dry adhesives is 50 to 60%.
In this example, the disintegration times of the tablets are determined in addition. Whereas the standard tablets not containing any dry adhesives disintegrate after an average time of 35 seconds, the tablets made according to the invention containing cellulose or methyl cellulose, respectively, disintegrate after about 20 seconds.
Aside from the foregoing active ingredients, this invention is applicable to the production of tablets from any pha-rmaceutically active powder. Illustrative is the adaptability of this invention for the manufacture of tablets from the following table:
THERAPEUTICALLY ACTIVE COMPOUND TABLE Amphetamine Ascorbic acid (vitamin C) Barbituric acid and derivatives, such as Barbital Cyclobarbital Phenobarbital sodium Biotin Bromelin Calcium pantothenate Carbachol Carisoprodol Chlormadinone Chlorothiazide Cortisone Cyanocobalamin (vitamin B Dexamethasone Didydrohyd'roxycodeinone-hydrochloride Digitoxin Erogocristine Erogonovine Estradiol Eupaverine Fencamfamin Hydrochlorothiazide Hydrocortisone 7 J 2-hydroxypropyl) -theophyl lin Isopropyl antipyrine Lanatoside C l7a-methyl testosterone Morphine Nicotinarnide Pancereatin Parabromdylamine Penicillin and derivatives, such as Phenoxymethyl penicillin Phenoxyethyl penicillin Piperazine adipate Prednisolone Prednisone Prednylidene Progesterone Pyridoxine (vitamin B and derivatives, such as Pyridoxine hydrochloride Pyridoxine phosphate Pyritinol Racephedrine hydrochloride Riboflavin (vitamin B Scopolamine Sulfanilamide and derivatives such as Sulfaperine 2-sulfanilamido-5-ethyl-pyrimidine Testosterone Tetracycline Thiamine (vitamin B and derivatives, such as Thiamine mononitrate Thiaminium orthophosphoric acid ester phosphate salt Thyreoidin Tiomesteron Trichloromethiazide The preceding examples can be repeated with similar success by substituting the generically and specifically described reactants and operating conditions of this invention for those used in the preceding examples.
From the foregoing description, one skilledin the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Consequently, such changes and modifications are properly, equitably, and intended to be, within the full range of equivalence of the following claims.
What is claimed is:
1. A process for producing nongranul ated directly d-rycompressed pharmaceutical tablets, which process comprises:
(a) homogeneously mixing or grinding into -99% by weight of dry powdery therapeutically active compound incapable of being dry-compressed to acceptable tablets directly without any preparation, and an excipient selected from the group consisting of lactose, starch, talc, finely divided silicia, magnesium stearate, and mixtures thereof, 110% by weight of at least one physiologically compatible powdery dry adhesive having a particle size of about 10 microns to 2 mm. selected from the group consisting of a normally solid polyethylene glycol, gelatin, dextrin, inulin, cellulose, carboxymethyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, alginic acids and their salts, a hemicellulose, and mixtures thereof; and
(b) directly compressing the resultant dry homogeneous powdery mixture under sufiicient high pressure to form a table of sufficient abrasion-resistance and solidity for pharmaceutical end uses.
2. A process as define-d by claim 1 wherein the concentration of dry adhesive is 2 to 5% by weight.
3. A process as defined in claim 1 wherein the dry adhesive is a polyethylene glycol.
4. A process as defined by claim 1 wherein the dry adhesive is gelatin.
5. A process as defined by claim 1 wherein the dry adhesive is cellulose.
6. A pharmaceutical tablet as produced by the process of claim 1.
7. A pharmaceutical tablet as produced by the process of claim 3.
8. A pharmaceutical tablet as produced by the process of claim 4.
9. A process as defined by claim 1 wherein the dry adhesive is a native beech cellulose powder having the properties set forth in the Beech Cellulose Table.
10. A pharmaceutical tablet as produced 'by the process of claim 9.
11. A process as defined by claim 1 wherein said oompressing step is conducted at 1000l0,000 atmospheres.
12. A pharmaceutical tablet as produced by the process of claim 5.
13. A process as defined by claim 1 wherein said therapeutically active compound consists essentially of at least one compound under said Therapeutically Active Compound Table.
14. A pharmaceutical tablet as produced by the process of claim 13.
15. A process as defined by claim 1 wherein said excipient consists essentially of starch.
16. A pharmaceutical tablet as produced by the process of claim 15.
17. A process as defined by claim 1 wherein said excipient consists essentially of talc.
18. A pharmaceutical tablet as produced by the process of claim 17.
19. A process as defined by claim 1 wherein said excipient consists essentially of finely divided silica.
20. A pharmaceutical tablet as produced by the process of claim 19.
21. A process as defined by claim 1 wherein said excipient consists essentially of magnesium stearate.
22. A pharmaceutical tablet as produced by the proces of claim 21.
23. A process as defined by claim -1 wherein said excipient is selected from the group consisting of starch, talc, finely divided silicia, magnesium stearate and mixtures thereof.
24. A pharmaceutical tablet as produced by the process of claim 23.
References Cited UNITED STATES PATENTS 1,613,362 1/19-27 Sheppard et a1. 264123 XR 8 Haavardsholm 264109 Steams 16782 Smedresrnan 16782 Christenson et al. a- 167-82 Rudski 167-82 Ferrand 16782 Siegel et a1. ..167-82 XR De Jong 167-82 Cyr et a1. 167-82 Stevens et al 167-82 LEWIS GO'ITS, Primary Examiner.
SHEP K. ROSE, Assistant Examiner.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US1613362 *||28 Apr 1926||4 Jan 1927||Eastman Kodak Co||Cake of compressed gelatin powder and process of making the same|
|US1770573 *||30 Jun 1928||15 Jul 1930||Olav Haavardsholm||Gelatin product and the process for manufacturing same|
|US2951791 *||31 Aug 1959||6 Sep 1960||American Cyanamid Co||Use of calcium silicate in tablet compressing|
|US3015611 *||25 Aug 1959||2 Jan 1962||Nysco Lab Inc||Low density whey-bound tablets|
|US3065143 *||19 Apr 1960||20 Nov 1962||Richardson Merrell Inc||Sustained release tablet|
|US3096248 *||6 Apr 1959||2 Jul 1963||Rexall Drug & Chemical Company||Method of making an encapsulated tablet|
|US3101299 *||30 Oct 1961||20 Aug 1963||Parisienne D Expansion Chimiqu||Silica-gel powder tablet compositions|
|US3116204 *||9 Nov 1961||31 Dec 1963||Merck & Co Inc||Pharmaceutical compositions and method of preparing the same|
|US3266992 *||22 Jan 1963||16 Aug 1966||Organon Nv||Tablets and method of preparing the same|
|US3312594 *||21 Jun 1963||4 Apr 1967||Squibb & Sons Inc||Longlasting troche|
|US3344030 *||15 Jun 1964||26 Sep 1967||American Home Prod||Reinforced directly compressed nongranulated pharmaceutical crystalline lactose tables|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3622677 *||7 Jul 1969||23 Nov 1971||Staley Mfg Co A E||Compressed tablets containing compacted starch as binder-disintegrant ingredient|
|US3627885 *||18 Jul 1968||14 Dec 1971||Rit Rech Ind Therapeut||Stabilized antibiotic compositions for animal feeding|
|US3692896 *||3 Mar 1971||19 Sep 1972||Isumura Juntendo Co Ltd||Process for the preparation of water-soluble tablets|
|US3725556 *||12 Nov 1970||3 Apr 1973||D Hanssen||Method of manufacturing rapidly disintegrating pharmaceutical tablets|
|US3852421 *||20 Sep 1971||3 Dec 1974||Shinetsu Chemical Co||Excipient and shaped medicaments prepared therewith|
|US3870790 *||25 Oct 1972||11 Mar 1975||Forest Laboratories||Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose|
|US3881005 *||13 Aug 1973||29 Apr 1975||Lilly Co Eli||Pharmaceutical dispersible powder of sitosterols and a method for the preparation thereof|
|US3885026 *||10 Sep 1973||20 May 1975||Boehringer Mannheim Gmbh||Preparation of porous tablets|
|US3900569 *||15 Sep 1972||19 Aug 1975||Sucrest Corp||Direct compression vehicle|
|US3946110 *||10 Feb 1975||23 Mar 1976||Peter, Strong Research And Development Company, Inc.||Medicinal compositions and methods of preparing the same|
|US3961004 *||11 Apr 1974||1 Jun 1976||Auburn Research Foundation||Method of tabletting using gluconolactone as the direct compression diluent|
|US3987204 *||24 Apr 1975||19 Oct 1976||Sucrest Corporation||Direct compression vehicle|
|US4013820 *||7 Nov 1974||22 Mar 1977||Abbott Laboratories||Universally useable tableting ingredients|
|US4097606 *||8 Oct 1975||27 Jun 1978||Bristol-Myers Company||APAP Tablet containing an alkali metal carboxymethylated starch and processes for manufacturing same|
|US4115563 *||14 Mar 1977||19 Sep 1978||Sterling Drug Inc.||Pharmaceutical steroid formulation|
|US4143129 *||16 Jan 1978||6 Mar 1979||Lilly Industries Limited||Cephalexin tablets|
|US4179497 *||13 Nov 1978||18 Dec 1979||Merck & Co., Inc.||Solid state ophthalmic medication|
|US4209513 *||14 Apr 1978||24 Jun 1980||Burroughs Wellcome Co.||Tablet formulation|
|US4226849 *||14 Jun 1979||7 Oct 1980||Forest Laboratories Inc.||Sustained release therapeutic compositions|
|US4254099 *||1 Oct 1979||3 Mar 1981||Beiersdorf Aktiengesellschaft||Pharmaceutical tablet composition|
|US4259314 *||10 Dec 1979||31 Mar 1981||Hans Lowey||Method and composition for the preparation of controlled long-acting pharmaceuticals|
|US4264573 *||21 May 1979||28 Apr 1981||Rowell Laboratories, Inc.||Pharmaceutical formulation for slow release via controlled surface erosion|
|US4269723 *||20 Mar 1979||26 May 1981||Jeyes Group Limited||Process for making a lavatory cleansing block and use|
|US4325971 *||15 Nov 1979||20 Apr 1982||Beecham Group Limited||Metoclopramide/paracetamol tablets|
|US4349493 *||22 Dec 1980||14 Sep 1982||Olin Corporation||Briquets of hydrated calcium hypochlorite|
|US4380540 *||18 Jan 1982||19 Apr 1983||Beecham Group Limited||Tablets|
|US4382919 *||15 Sep 1980||10 May 1983||Bristol-Myers Company||Composition for treatment and prevention of malodorous generating skin conditions|
|US4393086 *||13 Mar 1981||12 Jul 1983||Yoshinari Masuyama||Dietary product containing glucomannan powder and method for preparing|
|US4432975 *||19 Oct 1981||21 Feb 1984||Icn Pharmaceuticals, Inc.||Process for introducing vitamin B-12 into the bloodstream|
|US4465660 *||21 Dec 1982||14 Aug 1984||Mead Johnson & Company||Sustained release tablet containing at least 95 percent theophylline|
|US4547358 *||4 Jun 1984||15 Oct 1985||Mead Johnson & Company||Sustained release tablet containing at least 95 percent theophylline|
|US4571333 *||14 Jun 1983||18 Feb 1986||Syntex (U.S.A.) Inc.||Controlled release naproxen and naproxen sodium tablets|
|US4572916 *||21 Nov 1983||25 Feb 1986||Tate & Lyle Public Limited Co.||Tablets|
|US4722802 *||26 Mar 1986||2 Feb 1988||The Drackett Company||Process for the manufacture of surfactant cleansing blocks and compositions thereof|
|US4803079 *||20 Dec 1985||7 Feb 1989||Syntex (U.S.A.) Inc.||Controlled release naproxen and naproxen sodium tablets|
|US4828839 *||29 Jan 1988||9 May 1989||Boehringer Mannheim Gmbh||Method for making a guar flour chewable dosage unit|
|US4849415 *||11 Jan 1985||18 Jul 1989||The Dow Chemical Company||Sustained release compositions|
|US5370878 *||30 Sep 1993||6 Dec 1994||Hallmark Pharmaceuticals, Inc.||Method for preparing a direct compression granulated acetaminophen composition|
|US5747068 *||18 Jul 1995||5 May 1998||Lilly S. A.||Flouxetine pharmaceutical formulations|
|US5773031 *||27 Feb 1996||30 Jun 1998||L. Perrigo Company||Acetaminophen sustained-release formulation|
|US5914128 *||22 Dec 1997||22 Jun 1999||Schering Corporation||Orally administrable solid dosage form|
|US5916594 *||22 Dec 1997||29 Jun 1999||Schering Corporation||Process of making solid ribavirin dosage forms|
|US6051252 *||7 May 1999||18 Apr 2000||Schering Corporation||Orally administrable solid dosage form|
|US6080428 *||14 Jan 1995||27 Jun 2000||Bova; David J.||Nicotinic acid compositions for treating hyperlipidemia and related methods therefor|
|US6126969 *||31 Oct 1997||3 Oct 2000||L. Perrigo Company||Immediate release/sustained release compressed tablets|
|US6129930 *||6 Mar 1997||10 Oct 2000||Bova; David J.||Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night|
|US6410500||21 Dec 1998||25 Jun 2002||Henkel Kommanditgesellschaft Auf Aktien||Moulded body dishwasher detergents with soil release polymers|
|US6455068 *||23 Dec 1996||24 Sep 2002||Onesta Nutrition, Inc.||Dietary fiber delivery system|
|US6506720||3 Sep 1999||14 Jan 2003||Henkel Kommanditgesellschaft Auf Aktien||Process for preparing household detergent or cleaner shapes|
|US6676967||31 Oct 1997||13 Jan 2004||Kos Pharmaceuticals, Inc.||Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia|
|US6746691||31 Oct 1997||8 Jun 2004||Kos Pharmaceuticals, Inc.||Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics|
|US6818229||31 Oct 1997||16 Nov 2004||Kos Pharmaceuticals, Inc.||Intermediate release nicotinic acid compositions for treating hyperlipidemia|
|US6982093||16 Jul 2002||3 Jan 2006||Onesta Nutrition, Incorporated||Dietary fiber delivery system|
|US7008912||28 Feb 1998||7 Mar 2006||Henkel Kgaa||Pressed piece which disintegrates in liquids|
|US7226620||4 May 2005||5 Jun 2007||Rhodia Inc.||Directly compressible tricalcium phosphate|
|US7387803||28 Jan 2005||17 Jun 2008||Cns, Inc.||Dietary fiber delivery system|
|US7452553||19 Aug 2004||18 Nov 2008||Cns, Inc.||Dietary fiber delivery system|
|US7521072||19 Aug 2004||21 Apr 2009||Cns, Inc.||Dietary fiber delivery system|
|US7648720||29 Aug 2008||19 Jan 2010||Cns, Inc.||Dietary fiber delivery system|
|US7998506||16 Aug 2011||Kos Life Sciences, Inc.||Nicotinic acid compositions for treating hyperlipidemia and related methods therefor|
|US20030049313 *||16 Jul 2002||13 Mar 2003||Licari Jerome J.||Dietary fiber delivery system|
|US20050016391 *||19 Aug 2004||27 Jan 2005||Onesta Nutrition, Inc.||Dietary fiber delivery system|
|US20050019377 *||19 Aug 2004||27 Jan 2005||Onesta Nutrition, Inc.||Dietary fiber delivery system|
|US20050118257 *||23 May 2003||2 Jun 2005||Bova David J.||Nicotinic acid compositions for treating hyperlipidemia and related methods therefor|
|US20050129758 *||28 Jan 2005||16 Jun 2005||Onesta Nutrition, Inc.||Dietary fiber delivery system|
|US20070224270 *||4 Jun 2007||27 Sep 2007||Bova David J||Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor|
|US20070225341 *||4 Jun 2007||27 Sep 2007||Bova David J||Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor|
|US20070225342 *||4 Jun 2007||27 Sep 2007||Bova David J||Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor|
|US20070232667 *||12 Jun 2007||4 Oct 2007||Eugenio Cefali||Methods for Treating Hyperlipidemia With Intermediate Release Nicotinic Acid Compositions Having Unique Biopharmaceutical Characteristics|
|US20070237819 *||4 Jun 2007||11 Oct 2007||Bova David J||Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor|
|US20080045573 *||15 Aug 2007||21 Feb 2008||Bova David J||Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia|
|US20080317938 *||29 Aug 2008||25 Dec 2008||Licari Jerome J||Dietary Fiber Delivery System|
|USRE39139 *||16 Apr 2003||20 Jun 2006||Henkel Kgaa||Process for preparing household detergent or cleaner shapes|
|EP0011490A2 *||15 Nov 1979||28 May 1980||Beecham Group Plc||Analgesic tablet and process for its preparation|
|U.S. Classification||424/94.21, 514/57, 514/960, 264/122, 424/94.65, 514/58, 264/117, 264/123, 264/109, 514/60, 514/54|
|Cooperative Classification||A61K9/2004, Y10S514/96|